Physician profile
Brett E Lewis
NPI 1306010806
$22,948.67
in general payments reported to CMS, 2019-2025
13 companies · $3,670 in 2025
The $3,670 reported for 2025 was more than what 93% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11K · 2021: $701 · 2022: $16.41 · 2023: $158 · 2024: $7,249 · 2025: $3,670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,460 · Consulting Fee: $3,300 · Food and Beverage: $1,213 · Travel and Lodging: $1,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,460.00 |
| Consulting Fee | $3,300.00 |
| Food and Beverage | $1,213.23 |
| Travel and Lodging | $1,103.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Varian Medical Systems, INC. | $11,154.29 | 2020 | |
| Lantheus Medical Imaging, INC. | $5,809.15 | 2024 | |
| Novartis Pharmaceuticals Corporation | $3,449.99 | 2022-2025 | |
| Telix Pharmaceuticals | $874.23 | 2024-2025 | Illuccix |
| Gt Medical Technologies, INC | $700.98 | 2021 | |
| Elekta, INC. | $569.59 | 2024 | |
| Progenics Pharmaceuticals, INC. | $145.13 | 2024 | |
| Reflexion Medical, INC. | $102.83 | 2023 | Reflexion Medical Radiotherapy System |
| Accuray Incorporated | $84.44 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.49 | 2023 | |
| Jazz Pharmaceuticals INC. | $19.14 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $17.41 | 2025 | Tagrisso |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.